General Information of the Drug (ID: M6APDG01378)
Name
Dipyridamole
Synonyms
2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; Agilease; Anginal; Antistenocardin; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Apotex Brand of Dipyridamole; Apricor; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Berlin-Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Cleridium 150; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; D 9766; Dipiridamol; Dipiridamol [INN-Spanish]; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Dipyridamolum; Dipyridamolum [INN-Latin]; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; IPRAD Brand of Dipyridamole; Iv Persantine; Justpertin; Kurantil; Miosen; Natyl; Novo-Dipiradol; Novopharm Brand of Dipyridamole; Peridamol; Permiltin; Permole, Persantine, Dipyridan, Dipyridamole; Persantin; Persantine; Persantine (TN); Piroan; Prandiol; Prandiol 75; Protangix; RA-8; Stenocardil; Stenocardiol; Stimolcardio; Usaf Ge-12
    Click to Show/Hide
Status
Approved
Structure
Formula
C24H40N8O4
InChI
1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
InChIKey
IZEKFCXSFNUWAM-UHFFFAOYSA-N
PubChem CID
3108
VARIDT Drug ID
DR00613
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Dipyridamole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dipyridamole through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Dipyridamole. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Dipyridamole through regulating the expression of P-glycoprotein 1 (ABCB1). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Dipyridamole. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Dipyridamole through regulating the expression of P-glycoprotein 1 (ABCB1). [1], [4]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
Ref 3 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 4 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.